公开(公告)号：US20240398798A1

公开(公告)日：2024-12-05

申请号：US18407729

申请日：2024-01-09

Applicant: Novartis AG

Inventor： Michaela Kneissel ,  Vito Guagnano ,  Diana Graus Porta ,  Simon Wöhrle

IPC: A61K31/506 ,  A61K31/59 ,  A61K33/06 ,  A61K33/42 ,  A61K38/17 ,  A61K38/29 ,  A61K45/06

Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

公开(公告)号：US20150072019A1

公开(公告)日：2015-03-12

申请号：US14388978

申请日：2013-03-29

Applicant: NOVARTIS AG

Inventor： Michaela Kneissel ,  Vito Gaugnano ,  Diana Graus Porta ,  Simon Wöhrle

IPC: A61K31/506 ,  A61K33/42 ,  A61K31/59 ,  A61K38/17 ,  A61K38/29 ,  A61K45/06 ,  A61K33/06

CPC classification number: A61K31/506 ,  A61K31/59 ,  A61K33/06 ,  A61K33/42 ,  A61K38/1709 ,  A61K38/29 ,  A61K45/06

Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

Abstract translation: 本发明一般涉及3-（2,6-二氯-3,5-二甲氧基 - 苯基）-1- {6- [4-（4-乙基 - 哌嗪-1-基） - 苯基氨基] - 嘧啶-4 - 基} -1-甲基 - 脲或其药学上可接受的盐或溶剂合物或包含3-（2,6-二氯-3,5-二甲氧基 - 苯基）-1- {6- [4-（4 - 乙基 - 哌嗪-1-基） - 苯基氨基] - 嘧啶-4-基）-1-甲基 - 脲或其药学上可接受的盐或溶剂化物，用于治疗X连锁低磷血症r r病（XLH），常染色体显性 低钠血症性r ets病（ADHR），常染色体隐性低磷血症性r ets病（ARHR），肿瘤诱导的软骨软​​化症，肾移植后低磷血症，表皮痣综合征，骨移植异常增生或McCune-Albright综合征。

公开(公告)号：US20210308132A1

公开(公告)日：2021-10-07

申请号：US16005966

申请日：2018-06-12

Applicant: Novartis AG

Inventor： Michaela Kneissel ,  Vito Guagnano ,  Diana Graus Porta ,  Simon Wöhrle

IPC: A61K31/506 ,  A61K45/06 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/29 ,  A61K31/59

Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

公开(公告)号：US10028955B2

公开(公告)日：2018-07-24

申请号：US15272633

申请日：2016-09-22

Applicant: Novartis AG

Inventor： Michaela Kneissel ,  Vito Guagnano ,  Diana Graus Porta ,  Simon Wöhrle

IPC: A61K31/506 ,  A61K45/06 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/29 ,  A61K31/59

Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.